Inluriyo

ATC：L02BA

治疗领域：Breast Neoplasms

药理分类：Endocrine therapy

修订号：1 · 最新影响 PI 的程序：VR/0000333242

适应症（原文）：Inluriyo is indicated as monotherapy for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1-mutation, who have disease progression following prior treatment with an endocrine based regimen (for biomarker-based patient selection, see section 4.2).In pre- or perimenopausal women, or men, Inluriyo should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.